News Archives - Precision Pathology

• PPLS Admin
• 0 Comments

By Christopher Gaida | Fact checked by Patrick Campbell https://www.patientcareonline.com/view/sputum-based-test-may-identify-drug-targets-in-asthma-copd Sputum flow cytometry identifies biologic targets (CD124/CD125) to personalize asthma and COPD treatment. New research suggesting noninvasive sputum analysis using flow cytometry can identify specific antibody drug receptors in patients with chronic respiratory diseases was presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2026 […]

• PPLS Admin
• 0 Comments

As published by US Medicine, the Voice of Federal Medicine by Mary Anne Dunkin | Aug 21, 2025 FORT SAM HOUSTON, TX — Lung cancer is the leading cause of cancer deaths in the United States. Early detection is vital, especially for veterans, who face a disproportionately high risk of lung cancer due to higher rates of smoking […]

• PPLS Admin
• 0 Comments

bioAffinity Technologies [NASDAQ:BIAF], a healthcare diagnostics company focused on cancer, would consider inbound approaches among financing options as it focuses on national expansion, two officials said.

• PPLS Admin
• 0 Comments

bioAffinity Technologies [NASDAQ:BIAF], a healthcare diagnostics company focused on cancer, would consider inbound approaches among financing options as it focuses on national expansion, two officials said.

• PPLS Admin
• 0 Comments

BioAffinity Technologies Inc. has secured a Certificate of Grant of Patent from the Japan Patent Office.

It’s a landmark win for one of San Antonio’s more promising biotech companies, opening the door for commercialization of its core product, CyPath Lung, in the Asian market.

• PPLS Admin
• 0 Comments

bioAffinity Technologies [NASDAQ:BIAF], a healthcare diagnostics company focused on cancer, would consider inbound approaches among financing options as it focuses on national expansion, two officials said.